Noninvasix will be the first company to monitor the severity of sepsis and septic shock non-invasively, enabling clinicians to diagnose and monitor the response to treatment of tissue hypoxia in real time. Incorporating Noninvasix into the ICU workflow allows clinicians to more quickly and accurately diagnose critically ill patients and tailor treatments to improve outcomes. Future developments, enhancements, and evidence will expand our technology's use and clinical impact in other indications and settings. Noninvasix is backed by 15 years of optoacoustic research and more than $6.5 million in research grants.